Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Clinical Pearls in Alopecia: Translating Research to Practice
Description
The presentation discusses recent advancements in the treatment of alopecia and how to effectively translate this research into clinical practice. The speaker emphasizes four main therapeutic categories, highlighting the importance of a thorough patient evaluation and the necessity of biopsy in identifying specific types of alopecia. Case studies illustrate the use of oral minoxidil for various alopecia forms beyond androgenetic alopecia, ensuring a broader application for treatment. Moreover, it underlines the effectiveness and relatively safe profile of recently approved JAK inhibitors for alopecia areata, encouraging their use even in patients with mild symptoms. The talk transitions to complementary and alternative medicine, suggesting effective natural treatment options like pumpkin seed oil and rosemary oil for patients preferring non-synthetic therapies. Lastly, dupilumab is presented as a promising alternative for patients who cannot use JAK inhibitors due to side effects. The overall message conveys the importance of personalized treatment approaches and staying informed about the evolving management of alopecia.
View moreConclusions
- Oral minoxidil is a safe and effective treatment option for various types of alopecia, including frontal fibrosing alopecia and lichen planopilaris.
- Oral minoxidil improves hair thickness and may be particularly beneficial when topical treatments are not tolerated.
- JAK inhibitors like baricitinib and ritlecitinib have an acceptable safety profile and can be considered for alopecia areata, even in patients with less severe forms.
- There is evidence supporting the use of gentle topical treatments, such as pumpkin seed oil and rosemary oil, for patients preferring natural remedies.
- Dupilumab can be a viable alternative for alopecia areata if JAK inhibitors are contraindicated or have failed.
- Clinicians should consider a range of treatment options tailored to patient preferences, including complementary and alternative medicine for alopecia.
- Desir N, Desai AD, Lipner SR. Increased Interest in Oral Minoxidil for Hair Loss Treatment Following Publication of August 2022 New York Times Article: A Google Trends Analysis. Skin Appendage Disord. 2024 Feb;10(1):46-49.
- Grant-Kels JM. JAAD Game Changer: Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2024 Feb;90(2):327.
- Vañó-Galván S, Trindade de Carvalho L, Saceda-Corralo D, et al. Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol. 2021 Jun;84(6):1684-1686.
- Villani A, Fabbrocini G, Ocampo-Candiani J, Ruggiero A, Ocampo-Garza SS. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1485-1492.
- Kazmi A, Moussa A, Bokhari L, et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023.
- Papierzewska M, Waśkiel-Burnat A, Rudnicka L. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review. Clin Drug Investig. 2023 May;43(5):325-334.
- Sechi A, Song J, Dell'Antonia M, Heidemeyer K, Piraccini BM, Starace M, Naldi L. Adverse events in patients treated with Jak-inhibitors for alopecia areata: A systematic review. J Eur Acad Dermatol Venereol. 2023 Apr 4.
- Ufomadu P. Complementary and alternative supplements: a review of dermatologic effectiveness for androgenetic alopecia. Proc (Bayl Univ Med Cent). 2023 Dec 20;37(1):111-117.
- Wu S, Kou X, Niu Y, et al. Progress on the mechanism of natural products alleviating androgenetic alopecia. Eur J Med Chem. 2024 Jan 15;264:116022.
- Velho P, Rebelo CS, Macedo EA. Extraction of Gallic Acid and Ferulic Acid for Application in Hair Supplements. Molecules. 2023 Mar 4;28(5):2369.
- Starace M, Cedirian S, Bruni F, et al. Clinical study on the efficacy and tolerability of an oral supplement based on arginine, I-cystine, zinc and B6 vitamin (Cystiphane®) in patients with telogen effluvium. Ital J Dermatol Venerol. 2023 Jun;158(3):255-261.
- Milani M, Colombo F; GFM-O-Trial Investigators Group. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3-month, controlled, assessor-blinded study. Skin Res Technol. 2023 Jun;29(6):e13381.
- Cai L, Wei Y, Zhao M, Zhuo J, Tao X, Lin M. Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib. Front Med (Lausanne). 2023 Oct 9;10:1253795.
- Huang J, Jian J, Li T, Li M, Luo K, Deng S,Tang Y, Liu F, Zhao Z, Shi W,Li J. Dupilumab therapy for alopecia areata: a case series and review of the literature. J Dermatolog Treat. 2024 Dec;35(1):2312245.
- Husein-ElAhmed H, Husein-ElAhmed S. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis. J Eur Acad Dermatol Venereol. 2024 Jan 26.
- Gupta AK, Wang T, Bamimore MA, Piguet V, Tosti A. The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials. J Cosmet Dermatol. 2023 Sep;22(9):2553-2559.
- Lopez-Bernal T, Mazaira Fernández M, Vargas-Machuca Salido I, Aranegui B. Corneal Transplant Rejection and Alopecia Areata Universalis in a Patient With Severe Atopic Dermatitis on Dupilumab. Actas Dermosifiliogr. 2023 Dec 28:S0001-7310(23)01003-7.
- Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study. J Dermatol. 2023 Jul;50(7):880-887.